After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Dollar Tree Sticker Haul Which is your favorite pack? Senate Democrats block government funding bill for 13th time Car dashcam captures near-collision with US Air Force plane Teenager charged with ...

We recently published 10 Best Biotech Stocks to Buy Under $10. Recursion Pharmaceuticals, Inc. is placed eighth among them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage ...

The footage, which has racked up over 3.8 million views, has fueled calls for boycotts and comparisons to pricier rivals like Dollar General. Many shoppers said they’re disgusted by price increases ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...